Fangzhou Inc. Recognized as an "Outstanding Enterprise in Digital Intelligence" by Analysys Star

2024-12-18 IDOPRESS

HANGZHOU,China,Dec. 17,2024 -- Fangzhou Inc.("Fangzhou" or the "Company") (06086.HK),a leader in Internet healthcare solutions,was recognized as an "Outstanding Enterprise in Digital Intelligence" on the "Analysys Star 2024 Annual Award List" (released December 10th),alongside prominent Internet players such as Alibaba and ByteDance. Fangzhou was selected for its substantial contributions to advancing the use of digital intelligence in the Internet healthcare sector and chronic disease management. The company's innovative "H2H Smart Healthcare Platform" utilizes advanced technologies,including AI assistants and big data to improve healthcare accessibility and delivery,facilitating the digital transformation of the healthcare industry.

Dr. Xie Fangmin,founder,chairman,and CEO of Fangzhou,stated,"We are proud to be included among such distinguished industry peers on Analysys Star's 2024 Annual Award List,and Fangzhou looks forward collaborating with our close partners on the continued development of China's Internet healthcare sector."

As part of its commitment to embracing digital transformation,Fangzhou hosted a series of summits on "Data and AI: Decoding Digital Engagement" in various cities across China,including Shanghai,Chengdu,and Beijing. At these events,the Company showcased its innovative solutions and successful experiences in Internet healthcare with industry partners,providing valuable insights on the effective implementation of digital healthcare solutions.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30,2024),the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details,visit https://investors.jianke.com.

About the "Analysys Star Annual Award List"

Analysys International is a leading technology and market analysis firm focused on providing intelligence and research on China's digital economy. For more than 10 years,the "Analysys Star Annual Award List" has showcased significant achievements in China's digital economy sector. This year's awards were focused on the theme of emerging trends in "Digital Intelligence Innovation". Enterprises and their products were assessed across multiple dimensions including business models,technical strengths,user scale and experience,operational efficiency,and competitive strengths,with each award recipient having a profound influence on their respective industries.

Media Contact


For further inquiries or interviews,please reach out to:


Xingwei ZhaoAssociate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map